Kabidox

Kabidox has been found clinically effective in the treatment of a variety of infections caused
by susceptible strains of Gram-positive and Gram-negative bacteria and certain other micro-organisms.
•    Respiratory tract infections: Pneumonia and other lower respiratory tract infections due to susceptible strains of Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae and other organisms. Mycoplasma pneumoniae. Treatment of chronic bronchitis, sinusitis.
•    Urinary tract infections: Caused by susceptible strains of Klebsiella species, Enterobacter species, Escherichia coli, Streptococcus faecalis and other organisms.
•    Sexually transmitted diseases: Infections due to Chlamydia trachomatis including uncomplicated urethral, endocervical or rectal infections. Non-gonococcal urethritis caused by Ureaplasma urealyticum (T-mycoplasma). Kabidox is also indicated in chancroid, granuloma inguinale and lymphogranuloma venereum. Kabidox is an alternative drug in the treatment of gonorrhoea and syphilis.
•    Pelvic inflammatory disease
•    Rickettsial infections: Rocky Mountain spotted fever, typhus group, Q fever, Coxiella endocarditis and tick fevers.
•    Malaria
•    Dengue
•    Other infections: Psittacosis, brucellosis (in combination with streptomycin), cholera, bubonic plague, louse and tickborne relapsing fever, tularaemia glanders, melioidosis and acute intestinal amoebiasis (as an adjunct to amoebicides).
•    Kabidox is an alternative drug in the treatment gas gangrene and tetanus.
•    Kabidox is indicated for prophylaxis in the following conditions: Scrub typhus, travellers' diarrhoea (enterotoxigenic Escherichia coli), leptospirosis and malaria.
 

Packaging:

• Kabidox is supplied as a sterile lyophilized powder in a single-use glass vial with 10 ml sterile water for injection in FFS plastic ampoule.

Dosage:

• Adults: The usual dosage of Doxycycline I.V. is 200 mg on the first day of treatment administered in one or two infusions. Subsequent daily dosage is 100 to 200 mg depending upon the severity of infection, with 200 mg administered in one or two infusions. In the treatment of primary and secondary syphilis, the recommended dosage is 300 mg daily for at least 10 days. In the treatment of inhalational anthrax (post-exposure) the recommended dose is 100 mg of doxycycline, twice a day. Parenteral therapy is only indicated when oral therapy is not indicated and should not be continued over a prolonged period of time. Oral therapy should be instituted as soon as possible. Therapy must continue for a total of 60 days. 
• For children above eight years of age: The recommended dosage schedule for children weighing 100 pounds or less is 2 mg/lb of body weight on the first day of treatment, administered in one or two infusions. Subsequent daily dosage is 1 to 2 mg/lb of body weight given as one or two infusions, depending on the severity of the infection. For children over 100 pounds the usual adult dose should be used. In the treatment of inhalational anthrax (post-exposure) the recommended dose is 1 mg/lb (2.2 mg/kg) of body weight, twice a day in children weighing less than 100 lb (45 kg). Parenteral therapy is only indicated when oral therapy is not indicated and should not be continued over a prolonged period of time. Oral therapy should be instituted as soon as possible. Therapy must continue for a total of 60 days. 
   

• Each combipack contains:

(A)    Doxycycline for injection USP 100mg
Each vial contains:
Doxycycline Hydrochloride IP Equivalent to Doxycycline 100 mg
(B)    Sterile water for injections IP 10 ml
Each Ampoule contains:
Sterile water for injections IP 10 ml